%0 Journal Article
%A Merz, Maximilian
%A Salwender, Hans
%A Haenel, Mathias
%A Mai, Elias K
%A Bertsch, Uta
%A Kunz, Christina
%A Hielscher, Thomas
%A Blau, Igor W
%A Scheid, Christof
%A Hose, Dirk
%A Seckinger, Anja
%A Jauch, Anna
%A Hillengass, Jens
%A Raab, Marc-Steffen
%A Schurich, Baerbel
%A Munder, Markus
%A Schmidt-Wolf, Ingo G H
%A Gerecke, Christian
%A Lindemann, Hans-Walter
%A Zeis, Matthias
%A Weisel, Katja
%A Duerig, Jan
%A Goldschmidt, Hartmut
%T Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
%J Haematologica
%V 100
%N 7
%@ 1592-8721
%C Pavia
%I Ferrata Storti Foundation
%M DKFZ-2017-03148
%P 964 - 969
%D 2015
%X We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myeloma. Based on data from relapsed myeloma, the route of administration for bortezomib was changed from intravenous to subcutaneous after 314 of 604 patients had been enrolled. We analyzed 598 patients who received at least one dose of trial medication. Adverse events were reported more frequently in patients treated with intravenous bortezomib (intravenous=65
%K Antineoplastic Agents (NLM Chemicals)
%K Bortezomib (NLM Chemicals)
%K Dexamethasone (NLM Chemicals)
%K Doxorubicin (NLM Chemicals)
%K Cyclophosphamide (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:25840597
%2 pmc:PMC4486231
%R 10.3324/haematol.2015.124347
%U https://inrepo02.dkfz.de/record/127122